Effect of spirulina on risk of hospitalization among patients with COVID-19: the TOGETHER randomized trial.
Gilmar ReisEduardo Augusto Dos Santos Moreira SilvaDaniela Carla Medeiros SilvaLehana ThabaneThiago Santiago FerreiraCastilho Vitor Quirino Dos SantosAna Paula Figueiredo Guimaraes AlmeidaLeonardo Cançado Monteiro SavassiAdhemar Dias de Figueiredo NetoLuiza Lanna França ReisVitoria Helena de Souza CamposCarina BitarãesEduardo Diniz CallegariMaria Izabel Campos SimplicioLuciene Barra RibeiroRosemary OliveiraOfir HarariJamie I ForrestPrince Kumar LatLouis DronKristian ThorlundEdward J MillsPublished in: The American journal of clinical nutrition (2024)
Spirulina has no any clinical benefits as an outpatient therapy for COVID-19 compared with placebo with respect to reducing the retention in an emergency setting or COVID-19-related hospitalization. There are no differences between spirulina and placebo for other secondary outcomes. This trial was registered at clinicaltrials.gov as NCT04727424.